Kardigan Inc. Common Stock (KARD)
Stock · NASDAQ · Health Care
$13.05as of 10/16/2026
Price chart
Active signals
Resistance level
$20.05
Industry
Biotechnology: Pharmaceutical Preparations
About KARD
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-wo…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 241
- Website
- www.kardigan.bio
Fundamentals
- 1-day range
- $13.38$14.51
- Market cap
- $1.79B
- P/E (trailing)
- —
- P/E (forward)
- -4.60
- EPS (trailing)
- $-7.39
- Dividend yield
- —
- Beta
- 0.26
- Avg. volume
- 505.1K
52-week range
$12.23$27
Next earnings: November 9, 2026 · EPS estimate $-0.76
Forecasts
6 analyst ratings
Buy 90%
Hold 10%
Sell 0%
1-year price forecast
High
$46
+252.5%
Median
$39
+198.9%
Low
$25
+91.6%
Kardigan Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- KARDKardigan Inc. Common Stock$13.03▼ 6.12%Market cap $1.79BP/E —$12.23$27
- SEPNSepterna Inc. Common Stock$36.35▼ 2.94%Market cap $1.78BP/E —$17.55$51.1
- GENBGenerate Biomedicines Inc. Common Stock$12.09▼ 7.43%Market cap $1.78BP/E —$11$22.67
- SRPTSarepta Therapeutics Inc. Common Stock (DE)$17.1▼ 3.88%Market cap $1.77BP/E —$14.68$24.68
- SNDXSyndax Pharmaceuticals Inc. Common Stock$12.9▼ 5.49%Market cap $1.76BP/E —$12.99$25.59
- BCAXBicara Therapeutics Inc. Common Stock$16.78▼ 4.77%Market cap $1.81BP/E —$13.7$30.99
- CMPSCOMPASS Pathways Plc American Depository Shares$10.75▼ 7.49%Market cap $1.83BP/E —$4.88$15.87
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| KARD Kardigan Inc. Common Stock | $1.79B | — | $13.03 | ▼ 6.12% | $12.23$27 |
| SEPN Septerna Inc. Common Stock | $1.78B | — | $36.35 | ▼ 2.94% | $17.55$51.1 |
| GENB Generate Biomedicines Inc. Common Stock | $1.78B | — | $12.09 | ▼ 7.43% | $11$22.67 |
| SRPT Sarepta Therapeutics Inc. Common Stock (DE) | $1.77B | — | $17.1 | ▼ 3.88% | $14.68$24.68 |
| SNDX Syndax Pharmaceuticals Inc. Common Stock | $1.76B | — | $12.9 | ▼ 5.49% | $12.99$25.59 |
| BCAX Bicara Therapeutics Inc. Common Stock | $1.81B | — | $16.78 | ▼ 4.77% | $13.7$30.99 |
| CMPS COMPASS Pathways Plc American Depository Shares | $1.83B | — | $10.75 | ▼ 7.49% | $4.88$15.87 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- William Blair Initiates Coverage On Kardigan with Outperform Ratingbenzinga · 10/16/2026
- Kardigan Announces Appointment of Kristin Reinke to its Board of DirectorsYahoo · 9/30/2026
- Kardigan: Funded Precision Cardiology Offers More Than Pipeline DiversificationSeekingAlpha · 9/13/2026
Insider Activity
Insider Actions →Acquired
69.1K
Disposed
0
- Reinke Kristin Marie K · September 29, 2026 · Grant48.4K
- PERCEPTIVE ADVISORS LLC · June 17, 2026 · Grant20.7K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
UBS initiates coverage on Kardigan with $25 price target
UBS has started tracking Kardigan Inc. and set a price target of $25. This new analyst view is notable because it sits below the current average analyst target of $42.25. The stock is currently trading near its support level, which may reflect the mixed sentiment from this new coverage.
UBS initiates coverage on Kardigan with $25 price target. UBS has started tracking Kardigan Inc. and set a price target of $25. This new analyst view is notable because it sits below the current average analyst target of $42.25. The stock is currently trading near its support level, which may reflect the mixed sentiment from this new coverage.